Teva Pharmaceutical Indus... (TEVA)
NYSE: TEVA
· Real-Time Price · USD
17.79
0.25 (1.43%)
At close: Aug 15, 2025, 12:39 PM
Teva Pharmaceutical Industries Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -492M | -1.34B | -1.7B | -988M | -463M | -516M | -615M | -2.3B | -2.33B | -1.69B | -2.41B | -1.3B | -1.06B | -580M | 456M | 770M | -3.87B | -4.04B |
Depreciation & Amortization | 772M | 1.03B | 1.06B | 1.06B | 1.08B | 1.12B | 1.15B | 1.19B | 1.23B | 1.29B | 1.31B | 1.32B | 1.33B | 1.28B | 1.33B | 1.41B | 1.46B | 1.53B |
Stock-Based Compensation | 97M | 129M | 123M | 117M | 119M | 117M | 121M | 129M | 124M | 133M | 125M | 122M | 122M | 112M | 119M | 124M | 127M | 130M |
Other Working Capital | -628M | -638M | -435M | -611M | -1.53B | -1.69B | -1.51B | -1.43B | -999M | -478M | 99M | -1.03B | -1.06B | -2.02B | -3.83B | -4.32B | -4.75B | -4.48B |
Other Non-Cash Items | 2.1B | 4.05B | 5.22B | 4.56B | 3.37B | 2.14B | 1.1B | 2.48B | 3.37B | 2.53B | 2.48B | 1.2B | 339M | 695M | 714M | 843M | 5.79B | 5.95B |
Deferred Income Tax | -21M | -445M | -634M | -634M | -780M | -400M | -317M | -194M | 49M | -990M | -1.06B | -1.35B | -1.38B | -284M | -120M | -27M | -189M | -474M |
Change in Working Capital | -628M | -638M | -435M | 136M | -419M | -205M | -72M | -148M | 184M | 334M | 1.26B | 1.19B | 891M | -66M | -1.7B | -2.44B | -2.87B | -2.6B |
Operating Cash Flow | 1.39B | 1.58B | 1.86B | 2.47B | 1.78B | 1.68B | 1.37B | 1.16B | 1.7B | 1.49B | 1.59B | 1.07B | 1.06B | 1.15B | 798M | 673M | 451M | 506M |
Capital Expenditures | -404M | -501M | -498M | -488M | -489M | -511M | -526M | -549M | -522M | -530M | -548M | -559M | -583M | -569M | -562M | -585M | -582M | -600M |
Cash Acquisitions | 21M | 22M | -74M | -146M | -136M | -81M | n/a | 91M | 83M | 45M | 36M | -256M | -243M | -145M | n/a | 518M | 512M | 435M |
Purchase of Investments | -27M | -70M | -71M | -58M | -95M | -54M | -46M | -43M | -3M | -1M | -1M | -13M | 382M | 348M | 350M | 306M | -91M | -57M |
Sales Maturities Of Investments | 40M | 40M | 40M | -321M | -371M | n/a | n/a | 363M | 374M | 6M | 6M | 685M | 703M | 809M | 853M | 239M | 223M | 117M |
Other Investing Acitivies | 1.04B | 999M | 665M | 745M | 739M | 777M | 1.11B | 975M | 868M | 870M | 877M | 589M | 328M | 699M | 846M | 904M | 1.2B | 1.28B |
Investing Cash Flow | 671M | 532M | 116M | 215M | 131M | 572M | 968M | 837M | 800M | 677M | 657M | 733M | 874M | 1.18B | 1.52B | 1.42B | 1.29B | 1.12B |
Debt Repayment | -2.05B | -3.01B | -1.64B | -1.46B | -1.96B | -1B | -1.7B | -1.91B | -1.77B | -2.07B | -1.37B | -1.16B | -1.97B | -1.68B | -2.17B | -1.79B | -1.79B | -1.79B |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -365M | -375M | -150M | -237M | -313M | -358M | -212M | -139M | -137M | -124M | -117M | -115M | -43M | -2M | -6M | -6M | 110M | 108M |
Financial Cash Flow | -2.42B | -3.38B | -1.73B | -1.63B | -2.21B | -1.29B | -1.91B | -2.05B | -1.91B | -2.2B | -1.49B | -1.28B | -2.01B | -1.68B | -2.17B | -1.8B | -1.68B | -1.68B |
Net Cash Flow | -561M | -1.29B | 74M | 1.07B | -411M | 816M | 393M | -8M | 579M | -74M | 636M | 213M | -345M | 507M | 21M | 218M | 34M | -61M |
Free Cash Flow | 986M | 1.08B | 1.36B | 1.98B | 1.29B | 1.17B | 842M | 608M | 1.17B | 964M | 1.04B | 514M | 476M | 585M | 236M | 88M | -131M | -94M |